Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Challenges of correlating pH change with relief of clinical symptoms in gastro esophageal reflux disease: a phase III, randomized study of Zegerid versus Losec.

Walker D, Ng Kwet Shing R, Jones D, Gruss HJ, Reguła J.

PLoS One. 2015 Feb 23;10(2):e0116308. doi: 10.1371/journal.pone.0116308. eCollection 2015.

2.

Once-daily omeprazole/sodium bicarbonate heals severe refractory reflux esophagitis with morning or nighttime dosing.

Orbelo DM, Enders FT, Romero Y, Francis DL, Achem SR, Dabade TS, Crowell MD, Geno DM, DeJesus RS, Namasivayam V, Adamson SC, Arora AS, Majka AJ, Alexander JA, Murray JA, Lohse M, Diehl NN, Fredericksen M, Jung KW, Houston MS, O'Neil AE, Katzka DA.

Dig Dis Sci. 2015 Jan;60(1):146-62. doi: 10.1007/s10620-013-3017-y. Epub 2014 Jan 22.

PMID:
24448652
3.

Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial.

Pouchain D, Bigard MA, Liard F, Childs M, Decaudin A, McVey D.

BMC Gastroenterol. 2012 Feb 23;12:18. doi: 10.1186/1471-230X-12-18.

4.

Pharmacokinetics of two formulations of omeprazole administered through a gastrostomy tube in patients with severe neurodevelopmental problems.

Boussery K, De Smet J, De Cock P, Vande Velde S, Mehuys E, De Paepe P, Remon JP, Van Bocxlaer JF, Van Winckel M.

Br J Clin Pharmacol. 2011 Dec;72(6):990-6. doi: 10.1111/j.1365-2125.2011.04038.x.

5.

[On-demand treatment of nonerosive reflux disease: omeprazole plus bicarbonate powder versus omeprazole capsules].

Soifer L, Pedrana R, Parrota M, Gadea O, Naisberg G, Caruso N.

Acta Gastroenterol Latinoam. 2010 Sep;40(3):198-205. Spanish.

PMID:
21053477
6.

Pharmacokinetics of intrarectal omeprazole in alpacas.

Marmulak T, Stanley S, Kass PH, Wiebe V, McKemie D, Pusterla N.

J Vet Pharmacol Ther. 2010 Aug;33(4):371-5. doi: 10.1111/j.1365-2885.2009.01149.x.

PMID:
20646199
7.

Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States.

Graham DY, Javed SU, Keihanian S, Abudayyeh S, Opekun AR.

J Gastroenterol. 2010 Aug;45(8):816-20. doi: 10.1007/s00535-010-0220-x. Epub 2010 Mar 2.

PMID:
20195646
8.

[Acid suppression capacity of omeprazole, sodium bicarbonate and alginic acid in an oral powder combination].

Soifer L, Peralta AD, Arenoso H, Caruso N, Naisberg G.

Acta Gastroenterol Latinoam. 2009 Dec;39(4):261-6. Spanish.

PMID:
20178255
9.

Oral buffered esomeprazole is superior to i.v. pantoprazole for rapid rise of intragastric pH: a wireless pH metry analysis.

Banerjee R, Reddy DN, Guda NM, Kalpala R, Mahurkar S, Darisetty S, Rao GV.

J Gastroenterol Hepatol. 2010 Jan;25(1):43-7. doi: 10.1111/j.1440-1746.2009.05994.x. Epub 2009 Oct 27.

PMID:
19874444
10.

Alternative vs. conventional treatment given on-demand for gastroesophageal reflux disease: a randomised controlled trial.

Farup PG, Heibert M, Høeg V.

BMC Complement Altern Med. 2009 Feb 24;9:3. doi: 10.1186/1472-6882-9-3.

11.

Gastric acid and salivary bicarbonate. Is there a relationship in duodenal ulcer patients?

Namiot Z, Stasiewicz J, Markowski AR, Namiot DB, Jaroszewicz W, Kemona A, Górski J.

Rocz Akad Med Bialymst. 2004;49:75-9.

PMID:
15631318
12.

Oral bioavailability of pantoprazole suspended in sodium bicarbonate solution.

Ferron GM, Ku S, Abell M, Unruh M, Getsy J, Mayer PR, Paul J.

Am J Health Syst Pharm. 2003 Jul 1;60(13):1324-9.

PMID:
12901033
13.

Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects.

Doan TT, Wang Q, Griffin JS, Lukasik NL, O'Dea RF, Pan WJ.

Am J Health Syst Pharm. 2001 Aug 15;58(16):1512-9.

PMID:
11515348
14.

Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet.

Ley LM, Stahlheber-Dilg B, Sander P, Huber R, Mascher H, Lücker PW.

Methods Find Exp Clin Pharmacol. 2001 Jan-Feb;23(1):41-5.

PMID:
11413863
15.

Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate.

Sharma VK, Peyton B, Spears T, Raufman JP, Howden CW.

Aliment Pharmacol Ther. 2000 Jul;14(7):887-92.

16.

[Inhibition of gastric secretion by omeprazole and efficacy of calcium carbonate in the control of hyperphosphatemia in patients on maintenance hemodialysis].

Séchet A, Abighanem O, Said S, Rasombololona M, Morinière P, Brazier M, Fournier A.

Nephrologie. 1999;20(4):213-6. French.

PMID:
10480154
17.

Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis.

Hardy P, Sechet A, Hottelart C, Oprisiu R, Abighanem O, Said S, Rasombololona M, Brazier M, Moriniere P, Achard JM, Pruna A, Fournier A.

Artif Organs. 1998 Jul;22(7):569-73.

PMID:
9684693
18.

Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment.

el-Nujumi A, Williams C, Ardill JE, Oien K, McColl KE.

Gut. 1998 Feb;42(2):159-65.

19.

Reappraisal of bicarbonate secretion by the human oesophagus.

Mertz-Nielsen A, Hillingsø J, Bukhave K, Rask-Madsen J.

Gut. 1997 May;40(5):582-6.

20.

Omeprazole promotes proximal duodenal mucosal bicarbonate secretion in humans.

Mertz-Nielsen A, Hillingsø J, Bukhave K, Rask-Madsen J.

Gut. 1996 Jan;38(1):6-10.

Supplemental Content

Loading ...
Support Center